Maryam Niazi
Psychiatric/Mental Health · Columbus, OHNPI 1063706216
Payments from drug & device makers
Across 262 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$619
- E.r. Squibb & Sons, L.L.C.$582
- Axsome Therapeutics, Inc.$432
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$374
- Sunovion Pharmaceuticals Inc.$280
- plus $493 from 8 others
What the payments were for
- Food & beverage$4,38798%
- Education$932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 128 | $1,698 |
| Otsuka America Pharmaceutical, Inc. | 33 | $619 |
| E.r. Squibb & Sons, L.L.C. | 32 | $582 |
| Axsome Therapeutics, Inc. | 9 | $432 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $374 |
| Sunovion Pharmaceuticals Inc. | 19 | $280 |
| Alkermes, Inc. | 8 | $155 |
| Haemonetics Corporation | 1 | $102 |
| Lundbeck LLC | 4 | $84 |
| Neurocrine Biosciences, Inc. | 3 | $46 |
| Johnson & Johnson | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $26 |
| Indivior Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$243
- COBENFY$226
- ABILIFY ASIMTUFII$117
- ABILIFY MAINTENA$117
- VRAYLAR$115
How this compares
$4,479 in reported general payments places this provider in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 72 | $573,946 |
| Abilify MaintenaAripiprazole | 90 | $257,931 |
| Invega SustennaPaliperidone Palmitate | 34 | $124,427 |
| VraylarCariprazine Hcl | 74 | $105,255 |
| AustedoDeutetrabenazine | 14 | $71,544 |
| Lurasidone Hcl | 39 | $33,434 |
| CaplytaLumateperone Tosylate | 12 | $18,278 |
| RexultiBrexpiprazole | 11 | $17,370 |
| Aripiprazole | 97 | $14,870 |
| Chlorpromazine Hcl | 119 | $13,812 |
| Oxcarbazepine | 249 | $13,519 |
| Quetiapine Fumarate | 621 | $11,166 |
| Divalproex Sodium ErDivalproex Sodium | 201 | $8,024 |
| Paliperidone ErPaliperidone | 58 | $6,885 |
| Olanzapine | 232 | $4,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $46 | $573,94672 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $619 | $275,301101 claims |
| Johnson & JohnsonInvega Sustenna | $31 | $124,42734 claims |
| AbbVieVraylar | $1,698 | $105,25574 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $28 | $71,54414 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $374 | $18,27812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Columbus
- Holly SchweitzerColumbus$78K
- David HuffmanColumbus$50K
- Tarsicio GacheruColumbus$18K
- Alicja MatusiakColumbus$11K
- Summer LawsonColumbus$11K
- Gregory BlankenshipColumbus$10K
- Jennifer WilsonColumbus$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.